METhOD Patient Selection Five patients with histopathologically proven primary can cer and
radiographic and/or scintigraphic bony metastases werestudiedunderphysiciansIND27865 …

All patients were treated in single rooms with appropriate shielding to minimize exposure of
health care personnel. The †53Sm-EDTMPwas infused over 30 min by an infusion pump …

I452 The Journalof NuclearMedicine• Vol. 33 • No. 8 • August1992 more of the
following: x-ray,@ mTc@ HDPbone image, Cl'scan, MRI and bone biopsy. The study was …

A comment on this article appears in" Samarium-153-EDTMP dosimetry." J Nucl Med. 1994
Jan; 35 (1): 191-2. A comment on this article appears in" Biodistribution and dosimetry of …

Thirty-five patients with painful bone metastases arising from a variety of tumor types
underwent a clinical trial in which 153Sm-EDTMP was injected as a single intravenous …

Abstract 153 Sm-EDTMP (ethylenediaminetetramethylene phosphonate), prepared from a
kit, was administered to 28 patients in a clinical trial of therapy for painful skeletal …

Skeletal retention was calculated from unnary excretion. Re suits: No uptake of 1@ Sm-
EDTMPin nonskeletaltissues was observed in whole-body gamma camera images. The …

Various radioisotopes conjugated to pyrophosphate analogues have been developed for
systemic metabolic radiotherapy. Samarium-153-EDTMP is a 1: 1 complex of radioactive …

Reactor-produced samarium-153 (153 Sm) is both a beta and gamma emitter with a
physical half-life of 46.3 hours. When complexed with EDTMP, more than 50% of the …

Introduction: The optimal dose of samarium-153-EDTMP (153Sm-EDTMP) for effective
palliation of painful metastases to bone is under investigation. It is not known whether …